C OSBORNE to Adenocarcinoma
This is a "connection" page, showing publications C OSBORNE has written about Adenocarcinoma.
Connection Strength
0.168
-
Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study. Eur J Cancer. 1992; 28(2-3):477-8.
Score: 0.028
-
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 1992; 24(2):85-95.
Score: 0.028
-
Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. J Natl Cancer Inst. 1991 Aug 07; 83(15):1077-84.
Score: 0.027
-
Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study. Invest New Drugs. 1991 Feb; 9(1):87-8.
Score: 0.026
-
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009 Dec 19; 374(9707):2055-2063.
Score: 0.024
-
Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer. Cancer Treat Rep. 1983 Dec; 67(12):1133-5.
Score: 0.016
-
Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol. 1999 May; 17(5):1442-8.
Score: 0.012
-
Methods for determining chemosensitivity of MCF-7 cells in double-layer agar culture: labeling index depression and colony count inhibition. Stem Cells (1981). 1982; 2(1):34-44.
Score: 0.003
-
Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation. Mol Endocrinol. 2000 Mar; 14(3):369-81.
Score: 0.003